Autoimmune inflammatory myopathies

Handbook of Clinical Neurology

Volumn 86, Issue , 2007, Pages 273-301

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649333080     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)86014-3     Document Type: Review

References (215)

1. Amato A.A., Gronseth G.S., Jackson C.E., et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 40 (1996) 581-586
2. Amemiya K., Semino-Mora C., Granger R.P., et al. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94 (2000) 99-104
3. Amemiya K., Granger R.P., and Dalakas M.C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: studies in repeated muscle biopsies. Brain 123 (2000) 2030-2039
4. Arahata K., and Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 16 (1984) 209-215
5. Arahata K., and Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies III. Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 19 (1986) 112-125
6. Arahata K., and Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. V. Identification and quantitation of T8+ cytotoxic and T8 suppressor cells. Ann Neurol 23 (1988) 493-499
7. Arase S., Kato S., Nakanishi H., et al. Eosinophilic polymyositis induced by tranilast. J Dermatol 17 3 (1990) 182-186
8. Askanas V., and Engel W.K. Sporadic inclusion body myositis and hereditary inclusion-body myopathies. Arch Neurol 55 (1988) 915-920
9. Askanas V., and Engel W.K. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol 10 (1998) 530-542
10. Badrising U.A., Maat-Schieman M., van Duinen S.G., et al. Epidemiology of inclusion body myositis in the Netheralnds: a nationwide study. Neurology 55 (2000) 1385-1387
11. Badrising U.A., Maat-Schieman M., Ferrari M.D., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 51 (2002) 369-372
12. Badrising U.A., Schrender G.M.T.H., Giphart M.J., et al. Associations with autoimmune disorders and HLA class I, and II antigens in inclusion body myositis. Neurology 63 (2004) 2396-2398
13. Banker B.Q. Dermatomyositis of childhood. Ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol 35 (1975) 46-75
14. Barry M., and Bleackley R.C. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2 (2002) 401-409
15. Basta M., and Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94 (1994) 1729-1735
16. Behrens L., Bender A., Johnson M.A., et al. Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 120 (1997) 929
17. Behrens L., Kerschensteiner M., Misgeld T., et al. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 161 (1998) 5943-5951
18. Bender A., Ernst N., Iglesias A., et al. T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8 T cells. J Exp Med 181 (1995) 1863-1868
19. Bender A., Behrens L., Engel A.G., et al. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 84 (1998) 86-91
20. Benveniste O., Cherin P., Maisonobe T., et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomysitis patients. J Immunol 167 (2001) 3521-3529
21. Bohan A., and Peter J.B. Polymyositis and dermatomyositis. N Engl J Med 292 (1975) 344-347 403-407
22. Bombardieri S., Hughes G.R.V., Neri R., et al. Cyclophosphamide in severe polymyositis. Lancet 1 (1989) 1138-1139
23. Bronner I.M., Hoogendijk J.E., Wintzen A.R., et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 250 4 (2003) 480-485
24. Buchbinder R., Forbes A., Hall S., et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. Ann Intern Med 134 (2001) 1087-1095
25. Bunch T.W., Worthington J.W., Combs J.J., et al. Azathioprine and prednisone for polymyositis: a controlled clinical trial. Ann Intern Med 92 (1980) 365-369
26. Callen J.P. Dermatomyositis. Lancet 355 (2000) 53-57
27. Callen J.P. Relation between dermatomyositis and polymyositis and cancer. Lancet 357 (2001) 85-86
28. Callen J.P. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer?. Arch Dermatol 138 (2002) 969-971
29. Caproni M., Torchia D., and Cardinali C. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 151 (2004) 784-791
30. Carpenter S., Karpati G., Rothman S., et al. The childhood type of dermatomyositis. Neurology 26 (1976) 952-962
31. Cervenakova L., Sivakumar K., Nagel J., et al. Is hereditary inclusion body myopathy a "familial prion disease"?. Ann Neurol 40 (1996) 128
32. Chaudhry V., Cornblath D.R., Griffin J.W., et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56 (2001) 94-96
33. Cherin P., Herson S., Wechsler B., et al. Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients. Am J Med 91 (1991) 162-168
34. Cherin P., Pelletier S., Teixeira A., et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46 (2002) 467-474
35. Choi Y.C., and Dalakas M.C. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 54 (2000) 65-71
36. Choy E., and Isenberg D.A. Treatment of dermatomyositis and polymyositis. Rheumatology (Review) 41 (2002) 7-13
37. Confalomeri P., Bernasconi P., Megna P., et al. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 59 (2000) 164-169
38. Cronin M.E., Miller F.W., Hicks J.E., et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 16 (1989) 1225-1228
39. Cupler E.J., Leon-Monzon M., Miller J., et al. Inclusion body myositis in HIV-I and HTLV-I infected patients. Brain 119 (1996) 1887-1893
40. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325 (1991) 1487-1498
41. Dalakas M.C. How to diagnose and treat the inflammatory myopathies. Semin Neurol 92 (1994) 365-369
42. Dalakas M.C. Calcifications in dermatomyositis. N Engl J Med 333 (1995) 978
43. Dalakas M.C. Immunopathogenesis of inflammatory myopathies. Ann Neurol 37 Suppl. 1 (1995) S74-S86
44. Dalakas M.C. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 126 (1997) 721-730
45. Dalakas M.C. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 55 (1998) 1509-1512
46. Dalakas M.C. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology 51 (1998) 537-545
47. Dalakas M.C. Progress in inflammatory myopathies: good but not good enough. Editorial. J Neurol Neurosurg Psychiatry 70 (2001) 569-573
48. Dalakas M.C. The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 1 (2001) 300-306
49. Dalakas M.C. Understanding the immunopathogenesis of inclusion body myositis: present and future prospects. Rev Neurol 158 (2002) 948-958
50. Dalakas M.C. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 28 (2002) 779-798
51. Dalakas M.C. Therapeutic approaches in inflammatory myopathies. Semin Neurol 23 (2003) 199-206
52. Dalakas M.C. Polymyositis, dermatomyositis and inclusion body myositis. In: Fauci A.S., Kasper D.L., Braunwald E., et al. (Eds). Harrison's Principles of Internal Medicine. 16th edn. (2004), McGraw-Hill, New York 2540-2545
53. Dalakas M.C. Viral related muscle disease. In: Engel A.G. (Ed). Myology. 3rd edn. (2004), McGraw Hill, New York 1389-1417
54. Dalakas M.C. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 17 (2004) 561-567
55. Dalakas M.C. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 66 (2006) S33-S38
56. Dalakas M.C., and Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362 (2003) 971-982
57. Dalakas M.C., and Hohlfeld R. Diagnostic criteria for polymyositis and dermatomyositis. Lancet 362 (2003) 1762-1763
58. Dalakas M.C., and Illa I. Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann Neurol 37 (1995) 806-810
59. Dalakas M.C., and Karpati G. The inflammatory myopathies. In: Karpati G., Hilton-Jones D., and Griggs R.C. (Eds). Disorders of Voluntary Muscle. 7th edn. (2001), Cambridge University Press, Cambridge 636-659
60. Dalakas M.C., and Pezeshkpour G.H. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 23 S (1988) 38-48
61. Dalakas M.C., London W.T., Gravell M., et al. Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus. Neurology 36 (1986) 569-572
62. Dalakas M.C., Pezeshkpour G.H., Gravell M., et al. Polymyositis in patients with AIDS. JAMA 256 (1986) 2381-2383
63. Dalakas M.C., Illa I., Pezeshkpour G.H., et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 332 (1990) 1098-1105
64. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 329 (1993) 1993-2000
65. De Bleecker J., and Engel A.G. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol 146 (1995) 1178
66. De Bleecker J.L., Meire V.I., Declercq W., et al. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 9 (1999) 239
67. De Bleecker J.L., De Paepe B., Vanwalleghem I.E., et al. Differential expression of chemokines in inflammatory myopathies. Neurology 58 (2002) 1779-1785
68. De Rossi M., Bernasconi P., Baggi F., et al. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 12 (2000) 1329-1335
69. Douglas W.W., Tazelaar H.D., Hartman T.E., et al. Polymyositis-dermatomyositis associated interstitial lung disease. Am J Respir Crit Care Med 164 (2001) 1182-1185
70. Eisenberg I., Avidan N., Potikha T., et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 29 (2001) 83-87
71. Emslie-Smith A.M., and Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 27 (1990) 343-356
72. Emslie-Smith A.M., and Engel A.G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 41 6 (1991) 936-939
73. Emslie-Smith A.M., Arahata K., and Engel A.G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes and T-cell- mediated cytotoxicity in myopathies. Hum Pathol 20 (1989) 224-231
74. Engel A.G., Hohlfeld R., and Banker B.Q. The polymyositis and dermatomyositis syndromes. In: Engel A.G., and Franzini-Armstrong C. (Eds). Myology. 2nd edn. (1994), McGraw-Hill Book Co, New York 1335-1383
75. Fang M.A., Verity M.A., and Paulus H.E. Subacute perimyositis. J Rheumatol 15 8 (1988) 1291-1293
76. Ferrer I., Martin B., Castano J.G., et al. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 63 (2004) 484-498
77. Ferrer I., Carmona M., Blanco R., et al. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis. Brain Pathol 15 (2005) 101-108
78. Fidzianska A., Rowinska-Marcinska K., and Hausmanowa-Petrusewicz I. Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol 104 (2004) 197-203
79. Figarella-Branger D., Civate M., Bartoli C., et al. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28 6 (2003) 659-682
80. Friedman A.W., Targoff I.N., and Arnett F.C. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26 (1996) 459-467
81. Fyhr I.M., Moslemi A.R., Mosavi A.A., et al. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J Neuroimmunol 79 (1997) 185-189
82. Gallardo E., Rojas-Garcia R., de Luna N., et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57 11 (2001) 2136-2138
83. Garlepp M.J., and Mastaglia F.L. Autoantibodies in inflammatory myopathies. Am J Med Sci 319 (2000) 227-233
84. Garlepp M.J., Laing B., Zilko P.J., et al. HLA associations with inclusion body myositis. Clin Exp Immunol 98 (1994) 40-45
85. Garlepp M.J., Tabarias H., van Bockxmeer F.M., et al. Apolipoprotein Ee4 in inclusion body myositis. Ann Neurol 38 (1995) 957-959
86. Garlepp M.J., Blechynden L., Tabarias H., et al. Genetic factors in sporadic inclusion body myositis. In: Askanas V., Serratice G., and Engel W.K. (Eds). Inclusion Body Myositis and Myopathies (1998), Cambridge University Press, Cambridge 177-185
87. Genge A., and Karpati G. Intermittent, high-dose intravenous glucocorticoid (GC) treatment (Rx) is preferred to high dose oral GC administration in adult dermatomyositis (DM). Neurology 48 (1997) A321
88. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis: an emerging entity. Lancet 352 (1998) 347-352
89. Goebels N., Michaelis D., Engelhardt M., et al. Differential expression of perforin in muscle-infiltrating T cell in polymyositis and dermatomyositis. J Clin Invest 97 (1996) 2905
90. Grau J.M., Herrero C., Casademont J., et al. Cyclosporine A as first choice for dermatomyositis. J Rheumatol 21 (1994) 381-382
91. Greenberg S.A., Pinkus J.L., Pinkus G.S., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57 5 (2005) 664-678
92. Griggs R.C., Askanas V., Di Mauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 38 (1995) 705-713
93. Haupt H.M., and Hutchins G.M. The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. Am J Cardiol 50 (1982) 998-1006
94. Hausmann G., Herrero C., Cid M.C., et al. Immunopathologic study of skin lesions in dermatomyositis. J Am Acad Dermatol 25 (1991) 225-230
95. Hengstmann G.J.D., van Engelen B.G.M., Egberts W.T.M.V., et al. Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 13 (2001) 476-482
96. Hengstman G.J.D., Brouwer R., Vree Egberts W.T.M., et al. Clinical and serological characteristics of 125 Dutch myositis patients. J Neurol 249 (2002) 69-75
97. Hertzman P.A., Blevins W.L., Mayer J., et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 322 (1990) 869-873
98. Hill C.L., Zhang Y., Sigurgeirsson B., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357 (2001) 96-100
99. Hilton-Jones D. Inflammatory myopathies. Curr Opin Neurol 14 (2001) 591-596
100. Hirakata M., and Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12 (2000) 501-508
101. Hofbauer M., Wiesener S., Babbe H., et al. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR and CDR3 spectratype analysis. Proc Natl Acad Sci USA 100 (2003) 4090-4095
102. Hohlfeld R., and Engel A.G. Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol 136 (1990) 503-508
103. Hohlfeld R., and Engel A.G. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 29 (1991) 498-507
104. Hohlfeld R., and Engel A.G. The immunobiology of muscle. Immunol Today 15 (1994) 269-274
105. Hohlfeld R., Engel A.G., Ii K., et al. Polymyositis mediated by T lymphocytes that express the γ/δ receptor. N Engl J Med 324 (1991) 877-881
106. Hollingsworth P.N., Garlepp M.J., and Dawkins R.L. Autoimmune diseases of muscle. In: Rose N.R., and MacKay I. (Eds). The Autoimmune Diseases. 3rd edn. (1998), Academic Press, San Diego 663-686
107. Huang K.W., and Chen X.H. Pathology of eosinophilic fasciitis and its relation to polymyositis. Can J Neurol Sci 14 4 (1987) 632-637
108. Illa I., Nath A., and Dalakas M.C. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann Neurol 29 (1991) 474-481
109. Illa I., Dinsmore S., and Dalakas M.C. Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by L-tryptophan. Hum Pathol 24 7 (1993) 702-709
110. Illa I., Gallardo E., Gimeno R., et al. Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies. Am J Pathol 151 (1997) 81-88
111. Kamm M.A., Dennett X., and Byrne E. Relapsing eosinophilic myositis - a cause of pseudothrombophlebitis in an alcoholic. J Rheumatol 14 4 (1987) 831-834
112. Karpati G., Pouliot Y., and Carpenter S. Expression of immunoreactive major histocapability complex products in human skeletal muscles. Ann Neurol 23 (1988) 64-72
113. Kaufman L.D., Kephart G.M., Seidman R.J., et al. The spectrum of eosinophilic myositis. Clinical and immunopathogenic studies of three patients, and review of the literature. Arthritis Rheum 36 7 (1988) 1014-1024
114. Kieseier B.C., Schneider C., Clements J.M., et al. Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 124 (2001) 341-351
115. Kissel J.T., Mendell J.R., and Rammohan K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314 (1986) 329-334
116. Kissel J.T., Halterman R.K., Rammohan K.W., et al. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 48 (1991) 26-30
117. Knutsen A.P., Shah M., Schwarz K.B., et al. Graft versus host-like illness in a child with phenobarbital hypersensitivity. Pediatrics 78 (1986) 581-584
118. Koffman B.M., Sivakumar K., Simonis T., et al. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 84 (1998) 139-142
119. Kok C.C., Croager E.J., Witt C.S., et al. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Immunogenetics 49 (1999) 508-516
120. Kok C.C., Boyt A., Gaudieri S., et al. Mitochondrial DNA variants in inclusion body myositis and Alzheimer's disease. Neuromuscul Disord 10 (2000) 604-611
121. Krummel M.F., and Davis M.M. Dynamics of the immunological synapse: finding, establishing and solidifying a connection. Curr Opin Immunol 14 (2002) 66-74
122. Lakhanpal S., Lie J.T., Conn D.L., et al. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 46 (1987) 23-29
123. Layzer R.B., Shearn M.A., and Satya-Murti S. Eosinophilic polymyositis. Ann Neurol 1 1 (1977) 65-71
124. Leff R.L., Love L.A., Miller F.W., et al. Viruses in the idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 339 (1992) 1192-1195
125. Leon-Monzon M., and Dalakas M.C. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. Ann Neurol 32 (1992) 219-222
126. Leon-Monzon M., Lamperth L., and Dalakas M.C. Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV-polymyositis. Muscle Nerve 16 (1993) 408-413
127. Leon-Monzon M., Illa I., and Dalakas M.C. Polymyositis in patients infected with HTLV-I: the role of the virus in the cause of the disease. Ann Neurol 36 (1994) 643-649
128. Lewis W., and Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat Med 1 (1995) 417-422
129. Li M., and Dalakas M.C. Expression of human IAP-like protein in skeletal muscle: an explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies. J Neuroimmunol 106 (2000) 1-5
130. Liang L., and Sha W.C. The right place at the right time: novel B7 family members regulate effcetor T cell function. Curr Opin Immunol 14 (2002) 384-390
131. Lindberg C., Trysberg E., Tarkowski A., et al. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 61 (2003) 260-262
132. Love L.A., Leff R.L., Frazer D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70 (1991) 360-374
133. Luciano C.A., and Dalakas M.C. Inclusion body myositis: no evidence for a neurogenic component. Neurology 48 (1997) 29-33
134. Lundberg I., Brengman J.M., and Engel A.G. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne's dystrophy and non-weak controls. J Neuroimmunol 63 (1995) 9-16
135. Magro C.M., and Crowson A.N. The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus. J Cutan Pathol 24 (1997) 543-552
136. Mantegazza R., Hughes S.M., Mitchell D., et al. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology 41 (1991) 1128-1132
137. Mantegazza R., Andreetta F., Bernasconi P., et al. Analysis of T cell receptor repertoire of muscle infiltrating T lymphocytes in polymyositis: restricted V a/b rearrangements may indicated antigen-driven selection. J Clin Invest 91 (1993) 2880-2886
138. Marie I., Hachulla E., Hatron P.Y., et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28 (2001) 2230-2237
139. Mastaglia F.L. Treatment of autoimmune inflammatory myopathies. Curr Opin Neurol 13 (2000) 507-509
140. Mastaglia F.L., and Phillips B.A. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 28 (2002) 723-741
141. Mastaglia F.L., Phillips B.A., and Zilko P.J. Treatment of inflammatory myopathies. Muscle Nerve 20 (1997) 651-664
142. Mastaglia F.L., Phillips B.A., and Zilko P.J. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 65 (1998) 107-110
143. Mastaglia F.L., Phillips B.A., Zilko P.J., et al. Relapses in idiopathic inflammatory myopathies. Muscle Nerve 22 (1999) 1160-1161
144. Mastalgia F.L., Garlepp M.J., Phillips B.A., et al. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 27 (2003) 407-425
145. Matsubara S., Sawa Y., Takamori M., et al. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 57 (1994) 1008
146. Maugars Y.M., Berthelot J.M., Abbas A.A., et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 14 (1996) 263-274
147. Michaelis D., Goebels N., and Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 143 (1993) 1142-1149
148. Miller F.W., Leitman S.F., Cronin M.E., et al. A randomized double-blind controlled trial of plasma exchange and leukapheresis in patients with polymyositis and dermatomyositis. N Engl J Med 326 (1992) 1380-1384
149. Mimori T. Scleroderma-polymyositis overlap syndrome: clinical and serologic aspects. Int J Dermatol 26 (1987) 419-425
150. Monsonego A., Zota V., Karni A., et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest 114 (2003) 415-422
151. Morgan O., Rodgers-Johnson P., Mora C., et al. HTLV-1 and polymyositis in Jamaica. Lancet ii: 118 (1989) 4-1187
152. Mowzoon N., Sussman A., and Bradley W.G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 185 (2001) 119-122
153. Mukamel M., Horey G., and Mimori M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138 (2001) 763-766
154. Muntzing K., Lindberg C., Moslemi A.R., et al. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 58 (2003) 195-200
155. Murata K., and Dalakas M.C. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies. Am J Pathol 155 (1999) 453-460
156. Nagaraju K., Casciola-Rosen L., Rosen A., et al. The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 164 (2000) 5459-5465
157. Nagaraju K., Raben N., Loeffler L., et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 97 (2000) 9209-9214
158. Nishio J., Suzuki M., Miyasaka N., et al. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 167 (2001) 4051-4058
159. Nyberg P., Wikman A.L., Nennesmo I., et al. Increased expression of interleukin 1α and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 27 (2000) 940-948
160. Oddis C.V. Idiopathic inflammatory myopathy: management and prognosis. Rheum Dis Clin North Am 28 (2002) 979-1001
161. O'Hanlon T.P., Dalakas M.C., Plotz P.H., et al. Predominant T cell receptor variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 152 (1994) 2569-2576
162. Orth M., Tabrizi S.J., and Schapira A.H. Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology 55 8 (2000) 1235
163. Otero C., Illa I., and Dalakas M.C. Is there dermatomyositis (DM) without myositis?. Neurology 42 (1992) 388
164. Ozden S., Gessain A., Gout O., et al. Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy. Clin Infect Dis 32 (2001) 510-514
165. Ozden S., Cochet M., Mikol J., et al. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol 78 (2004) 10320-10327
166. Page G., and Miossex P. Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol 204 (2004) 28-38
167. Peng A., Koffman B.M., Malley J.D., et al. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 55 (2000) 296-298
168. Phillips B.A., and Mastaglia F.L. Exercise therapy in patients with myopathy. Curr Opin Neurol 13 (2000) 547-552
169. Phillips B.A., Zilko P.J., and Mastaglia F.L. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 23 (2000) 970-972
170. Plotz P.H., Dalakas M., Leff R.L., et al. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis and related disorders. Ann Intern Med 111 (1989) 143-157
171. Pluschke G., Ruegg D., Hohlfeld R., et al. Autoaggressive myocytotoxic T lymphocytes expressing an unusual γδ T cell receptor. J Exp Med 176 (1992) 1785-1789
172. Raju R., and Dalakas M.C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128 (2005) 1887-1896
173. Raju R., Vasconcelos O.M., Semino-Mora C., et al. Expression of interferon-gamma inducible chemokines in the muscles of patients with inclusion body myositis. J Neuroimmunol 141 (2003) 125-131
174. Ramanan A.V., and Feldman B.M. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28 (2002) 833-857
175. Reed A.M., and Ytterberg S.R. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28 (2002) 891-916
176. Reed A.M., Picornell Y.J., Harwood A., et al. Chimerism in children with juvenile dermatomyositis. Lancet 356 (2000) 2156-2157
177. Rosenberg N.L., Carry M.R., and Ringel S.P. Association of inflammatory myopathies with other connective tissue disorder and malignancies. In: Dalakas M.C. (Ed). Polymyositis and Dermatomyositis (1988), Butterworths, Boston 37-69
178. Saito M., Higuchi I., Saito A., et al. Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis 186 (2002) 1231-1241
179. + T cell cytotoxicity. Brain 127 (2004) 1182-1190
180. Schmidt J., Raju R., Salajegheh M., et al. Distinct interplay between inflammatory and degeneration-associated molecules in sporadic IBM. Neurology 64 Suppl. 1 (2005) A331-A338
181. Schneider C., Gold R., Dalakas M.C., et al. MHC class I mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 55 (1996) 1205-1209
182. Schneider C., Dalakas M.C., Toyka K.V., et al. T cell apoptosis in inflammatory neuromuscular disorders associated with human immunodeficiency virus infection. Arch Neurol 56 (1999) 79-83
183. Seidman R.J., Kaufman L.D., Sokoloff L., et al. The neuromuscular pathology of the eosinophilia-myalgia syndrome. J Neuropathol Exp Neurol 50 1 (1991) 49-62
184. Sekul E.A., and Dalakas M.C. Inclusion body myositis: new concepts. Semin Neurol 13 (1993) 256-263
185. Sekul E.A., Chow C., and Dalakas M.C. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 48 (1997) 863-866
186. Selcen D., Ohno K., and Engel A.G. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain 127 (2004) 439-451
187. Serratrice G., Pellissier J.F., Roux H., et al. Fasciitis, perimyositis, myositis, polymyositis, and eosinophilia. Muscle Nerve 13 5 (1990) 385-395
188. Shamin E.A., Rider L.G., and Miller F.W. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 12 (2000) 482-491
189. Shamin E.A., Rider L.G., Pandey J.P., et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians. Arthritis Rheum 46 (2002) 1885-1893
190. Shulman L.E. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome?. J Rheumatol 11 5 (1984) 569-570
191. Sigurgeirsson B., Lindelöf B., Edhag O., et al. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med 326 (1992) 363-367
192. Sivakumar K., and Dalakas M.C. The spectrum of familial inclusion body myopathies in 13 families and a description of a quadriceps-sparing phenotype in non-Iranian Jews. Neurology 47 (1996) 977-984
193. Sivakumar K., Cervenkova L., Dalakas M.C., et al. Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol 38 (1995) 267-269
194. Sivakumar K., Semino-Mora C., and Dalakas M.C. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. Brain 120 (1997) 653-661
195. Sontheimer R.D. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20 (2002) 387-408
196. Soueidan S.A., and Dalakas M.C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43 (1993) 876-879
197. Sparsa A., Liozon E., Herrmann F., et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis. Arch Dermatol 138 (2002) 885-890
198. Spector S.A., Lemmer M.S., Koffman B.M., et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 20 (1997) 1242-1248
199. Stein D.P., and Dalakas M.C. Intercellular adhesion molecule-I expression is upregulated in patients with dermatomyositis (DM). Ann Neurol 34 (1993) 268
200. Sugiura T., Kawaguchi Y., Harigai M., et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15 and monocyte chemoattractant protein-1 production. J Immunol 164 (2000) 6593-6600
201. Sultan S.M., Ioannou Y., Moss K., et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 41 (2002) 22-26
202. Tai P.C., Hayes D.J., Clark J.B., et al. Toxic effects of human eosimophil products on isolated rat heart muscles in vitro. Biochem J 204 (1982) 75-80
203. Targoff I.N. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin Norht Am 28 (2002) 859-890
204. Tews D.S., and Goebel H.H. Cytokine expression profiles in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55 (1996) 342-347
205. Tezak Z., Hoffman E.P., Lutz J.L., et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 168 (2002) 4154-4163
206. Trueb R.M., Becker-Wegerich P., Hafner J., et al. Relapsing eosinophilic perimyositis. Br J Dermatol 133 1 (1995) 109-114
207. Turi G.K., Solitare G.B., James N., et al. Eosinophilia-myalgia syndrome (L-tryptophan-associated neuromyopathy). Neurology 40 11 (1990) 1793-1796
208. Uncini A., Lange D.J., Hayes A.P., et al. Long-duration polyphasic motor unit potentials in myopathies: a quantitative study with pathological correlation. Muscle Nerve 13 (1990) 263-267
209. Walter M.C., Lochmuller H., Toepfer M., et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247 (2000) 22-28
210. Weller P.F. The immunobiology of eosinophils. N Engl J Med 324 16 (1991) 1110-1118
211. Werth V.P., Callen J.P., Ang G., et al. Associations of tumor necrosis factor α and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119 (2002) 617-620
212. Wiendl H., Behrens L., Maier S., et al. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol 48 (2000) 679-684
213. Wiendl H., Malotka J., Holzwarth B., et al. An autoreactive γδ TCR derived from a polymyositis lesion. J Immunol 169 (2002) 515-521
214. Wiendl H., Mitsdoerffer M., Hofmeister V., et al. The nonclassical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 126 (2003) 176-185
215. Wiendel H., Mitsdoerffer M., Schneider D., et al. Muscle fibers and cultured muscle or cells express the B7.1/2 related costimulatory molecule ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126 (2003) 1026-1035